|
[1]
|
Broers, M.C., Bunschoten, C., Nieboer, D., et al. (2019) Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology, 52, 161-172. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Mcleod, J.G., Pollard, J.D., Macaskill, P., et al. (1999) Prevalence of Chronic Inflammatory Demyelinating Polyneuropathy in New South Wales, Australia. Annals of Neurology, 46, 910-913. [Google Scholar] [CrossRef]
|
|
[3]
|
Kieseier, B.C., Mathey, E.K., Sommer, C., et al. (2018) Immune-Mediated Neuropathies. Nature Reviews Disease Primers, 4, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Van Den Bergh, P.Y.K., Van Doorn, P.A., Hadden, R.D.M., et al. (2021) European Academy of Neurology/Peripheral Nerve Society Guideline on Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Report of a Joint Task Force—Second Revision. European Journal of Neurology, 28, 3556-3583. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Dyck, P.J., O’brien, P.C., Oviatt, K.F., et al. (1982) Prednisone Improves Chronic Inflammatory Demyelinating Polyradiculoneuropathy More than No Treatment. Annals of Neurology, 11, 136-141. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Hughes, R.A., Mehndiratta, M.M. and Rajabally, Y.A. (2017) Corticosteroids for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. The Cochrane Database of Systematic Reviews, No. 11, CD002062. [Google Scholar] [CrossRef]
|
|
[7]
|
Muley, S.A., Kelkar, P. and Parry, G.J. (2008) Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with Pulsed Oral Steroids. Archives of Neurology, 65, 1460-1464. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Börü, Ü.T., Erdoğan, H., Alp, R., et al. (2014) Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with High Dose Intravenous Methylprednisolone Monthly for Five Years: 10-Year Follow Up. Clinical Neurology and Neurosurgery, 118, 89-93. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lopate, G., Pestronk, A. and Al-Lozi, M. (2005) Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with High-Dose Intermittent Intravenous Methylprednisolone. Archives of Neurology, 62, 249-254. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Eftimov, F., Vermeulen, M., Van Doorn, P.A., et al. (2012) Long-Term Remission of CIDP after Pulsed Dexamethasone or Short-Term Prednisolone Treatment. Neurology, 78, 1079-1084. [Google Scholar] [CrossRef]
|
|
[11]
|
Van Schaik, I.N., Eftimov, F., Van Doorn, P.A., et al. (2010) Pulsed High-Dose Dexamethasone versus Standard Prednisolone Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (Predict Study): A Double-Blind, Randomised, Controlled Trial. The Lancet Neurology, 9, 245-253. [Google Scholar] [CrossRef]
|
|
[12]
|
Van Lieverloo, G.G.A., Peric, S., Doneddu, P.E., et al. (2018) Corticosteroids in Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective, Multicentre Study, Comparing Efficacy and Safety of Daily Prednisolone, Pulsed Dexamethasone, and Pulsed Intravenous Methylprednisolone. Journal of Neurology, 265, 2052-2059. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kimura, A., Sakurai, T., Koumura, A., et al. (2010) Motor-Dominant Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Neurology, 257, 621-629. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Doneddu, P.E., Cocito, D., Manganelli, F., et al. (2019) Atypical CIDP: Diagnostic Criteria, Progression and Treatment Response. Data from the Italian CIDP Database. Journal of Neurology, Neurosurgery, and Psychiatry, 90, 125-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mushtaq, T. and Ahmed, S.F. (2002) The Impact of Corticosteroids on Growth and Bone Health. Archives of Disease in Childhood, 87, 93-96. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Brannagan, T.H. (2009) Current Treatments of Chronic Immune-Mediated Demyelinating Polyneuropathies. Muscle & Nerve, 39, 563-578. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Eftimov, F., Winer, J.B., Vermeulen, M., et al. (2013) Intravenous Immunoglobulin for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. The Cochrane Database of Systematic Reviews, No. 12, CD001797. [Google Scholar] [CrossRef]
|
|
[18]
|
Kuitwaard, K., Hahn, A.F., Vermeulen, M., et al. (2015) Intravenous Immunoglobulin Response in Treatment-Naïve Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of Neurology, Neurosurgery, and Psychiatry, 86, 1331-1336. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Nobile-Orazio, E., Cocito, D., Jann, S., et al. (2015) Frequency and Time to Relapse after Discontinuing 6-Month Therapy with IVIg or Pulsed Methylprednisolone in CIDP. Journal of Neurology, Neurosurgery, and Psychiatry, 86, 729-734. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Latov, N., Deng, C., Dalakas, M.C., et al. (2010) Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 67, 802-807. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Hughes, R.A., Donofrio, P., Bril, V., et al. (2008) Intravenous Immune Globulin (10% Caprylate-Chromatography Purified) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (ICE Study): A Randomised Placebo-Controlled Trial. The Lancet Neurology, 7, 136-144. [Google Scholar] [CrossRef]
|
|
[22]
|
Kuwabara, S., Mori, M., Misawa, S., et al. (2017) Intravenous Immunoglobulin for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre, Open-Label, 52-Week Phase III Trial. Journal of Neurology, Neurosurgery, and Psychiatry, 88, 832-838. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Cornblath, D.R., Hartung, H.P., Katzberg, H.D., et al. (2018) A Randomised, Multi-Centre Phase III Study of 3 Different Doses of Intravenous Immunoglobulin 10% in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (ProCID Trial): Study Design and Protocol. Journal of the Peripheral Nervous System: JPNS, 23, 108-114. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Lunn, M.P., Ellis, L., Hadden, R.D., et al. (2016) A Proposed Dosing Algorithm for the Individualized Dosing of Human Immunoglobulin in Chronic Inflammatory Neuropathies. Journal of the Peripheral Nervous System: JPNS, 21, 33-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Kuitwaard, K., Brusse, E., Jacobs, B.C., et al. (2021) Randomized Trial of Intravenous Immunoglobulin Maintenance Treatment Regimens in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. European Journal of Neurology, 28, 286-296. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Kuitwaard, K., Fokkink, W.R., Brusse, E., et al. (2017) Maintenance IV Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of the Peripheral Nervous System: JPNS, 22, 425-432. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Markvardsen, L.H., Debost, J.C., Harbo, T., et al. (2013) Subcutaneous Immunoglobulin in Responders to Intravenous Therapy with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. European Journal of Neurology, 20, 836-842. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Markvardsen, L.H., Harbo, T., Sindrup, S.H., et al. (2014) Subcutaneous Immunoglobulin Preserves Muscle Strength in Chronic Inflammatory Demyelinating Polyneuropathy. European Journal of Neurology, 21, 1465-1470. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Van Schaik, I.N., Bril, V., Van Geloven, N., et al. (2018) Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Neurology, 17, 35-46.
|
|
[30]
|
Van Schaik, I.N., Mielke, O., Bril, V., et al. (2019) Long-Term Safety and Efficacy of Subcutaneous Immunoglobulin Igpro20 in CIDP: PATH Extension Study. Neurology: Neuroimmunology & Neuroinflammation, 6, e590. [Google Scholar] [CrossRef]
|
|
[31]
|
Markvardsen, L.H., Sindrup, S.H., Christiansen, I., et al. (2017) Subcutaneous Immunoglobulin as First-Line Therapy in Treatment-Naive Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Randomized Controlled Trial Study. European Journal of Neurology, 24, 412-418. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Dyck, P.J., Daube, J., O’brien, P., et al. (1986) Plasma Exchange in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. The New England Journal of Medicine, 314, 461-465. [Google Scholar] [CrossRef]
|
|
[33]
|
Hahn, A.F., Bolton, C.F., Pillay, N., et al. (1996) Plasma-Exchange Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: A Double-Blind, Sham-Controlled, Cross-Over Study. Brain: A Journal of Neurology, 119, 1055-1066. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Mehndiratta, M.M., Hughes, R.A. and Pritchard, J. (2015) Plasma Exchange for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. The Cochrane Database of Systematic Reviews, No. 8, CD003906. [Google Scholar] [CrossRef]
|
|
[35]
|
Mörtzell Henriksson, M., Newman, E., Witt, V., et al. (2016) Adverse Events in Apheresis: An Update of the WAA Registry Data. Transfusion and Apheresis Science, 54, 2-15.
|
|
[36]
|
Kiprov, D.D., Golden, P., Rohe, R., et al. (2001) Adverse Reactions Associated with Mobile Therapeutic Apheresis: Analysis of 17,940 Procedures. Journal of Clinical Apheresis, 16, 130-133. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Lieker, I., Slowinski, T., Harms, L., et al. (2017) A Prospective Study Comparing Tryptophan Immunoadsorption with Therapeutic Plasma Exchange for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Clinical Apheresis, 32, 486-493. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Dyck, P.J.B. and Tracy, J.A. (2018) History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clinic Proceedings, 93, 777-793.
|
|
[39]
|
Dyck, P.J., O’Brien, P., Swanson, C., et al. (1985) Combined Azathioprine and Prednisone in Chronic Inflammatory-Demyelinating Polyneuropathy. Neurology, 35, 1173-1176. [Google Scholar] [CrossRef]
|
|
[40]
|
Hadden, R.D., Sharrack, B., Bensa, S., et al. (1999) Randomized Trial of Interferon Beta-1a in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology, 53, 57-61. [Google Scholar] [CrossRef]
|
|
[41]
|
Mahdi-Rogers, M., Rutterford, C., Hughes, R.A.C., et al. (2009) Randomised Controlled Trial of Methotrexate for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (RMC Trial): A Pilot, Multicentre Study. The Lancet Neurology, 8, 158-164.
|
|
[42]
|
Hughes, R.A., Gorson, K.C., Cros, D., et al. (2010) Intramuscular Interferon Beta-1a in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology, 74, 651-657. [Google Scholar] [CrossRef]
|
|
[43]
|
Hughes, R., Dalakas, M.C., Merkies, I., et al. (2018) Oral Fingolimod for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP Trial): A Double-Blind, Multicentre, Randomised Controlled Trial. The Lancet Neurology, 17, 689-698.
|
|
[44]
|
Brannagan, T.H., Pradhan, A., Heiman-Patterson, T., et al. (2002) High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory CIDP. Neurology, 58, 1856-1858. [Google Scholar] [CrossRef]
|
|
[45]
|
Benedetti, L., Grandis, M., Nobbio, L., et al. (2004) Mycophenolate Mofetil in Dysimmune Neuropathies: A Preliminary Study. Muscle & Nerve, 29, 748-749. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Matsuda, M., Hoshi, K., Gono, T., et al. (2004) Cyclosporin A in Treatment of Refractory Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of the Neurological Sciences, 224, 29-35.
|
|
[47]
|
Gladstone, D.E., Prestrud, A.A. and Brannagan, T.H. (2005) High-Dose Cyclophosphamide results in Long-Term Disease Remission with Restoration of a Normal Quality of Life in Patients with Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy. Journal of the Peripheral Nervous System: JPNS, 10, 11-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Bedi, G., Brown, A., Tong, T., et al. (2010) Chronic Inflammatory Demyelinating Polyneuropathy Responsive to Mycophenolate Mofetil Therapy. Journal of Neurology, Neurosurgery, and Psychiatry, 81, 634-636. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Benedetti, L., Briani, C., Franciotta, D., et al. (2011) Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature. Journal of Neurology, Neurosurgery, and Psychiatry, 82, 306-308. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Cocito, D., Grimaldi, S., Paolasso, I., et al. (2011) Immunosuppressive Treatment in Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy. A Nationwide Retrospective Analysis. European Journal of Neurology, 18, 1417-1421. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Takeuchi, A., Shirai, S., Horiuchi, K., et al. (2012) Successful Cyclosporine Treatment in 2 Patients with Refractory Cidp, Involving Monitoring of Both AUC (0-4 h) and Trough Levels. Clinical Neurology, 52, 172-177.
|
|
[52]
|
Querol, L., Rojas-García, R., Diaz-Manera, J., et al. (2015) Rituximab in Treatment-Resistant CIDP with Antibodies against Paranodal Proteins. Neurology: Neuroimmunology & Neuroinflammation, 2, e149. [Google Scholar] [CrossRef]
|